Molecularly profiling colorectal cancer has opened many potential opportunities for the use of this information in therapeutic decision-making. However, at present, only RAS testing in the metastatic setting has a definitive place in the decision-making paradigm.
|Original language||English (US)|
|Journal||ONCOLOGY (United States)|
|State||Published - Feb 15 2014|
ASJC Scopus subject areas
- Cancer Research